Hausarztzentrum Butendorf
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The research at Hausarztzentrum Butendorf targets atherosclerotic cardiovascular disease and related conditions, seeking to improve heart health by lowering LDL‑cholesterol, reducing cardiovascular risk, and managing heart failure.
- Cardiovascular risk reduction in participants with elevated Lp(a)
- Hypercholesterolemia management
- Heart failure symptom improvement
- Prevention of major adverse cardiovascular events
- Evaluation of novel lipid‑lowering therapies
Through these studies, Hausarztzentrum Butendorf contributes to advancing preventive and therapeutic strategies for heart disease.
Digestive System Diseases
Investigations focus on functional gastrointestinal disorders, particularly irritable bowel syndrome, evaluating probiotic treatments to ease symptoms and improve quality of life.
- Irritable bowel syndrome (diarrhoea‑predominant)
- Gut microbiome modulation
- Symptom frequency and severity reduction
- Safety and tolerability of oral bacterial therapy
- Patient‑reported outcome improvements
The centre’s work supports the development of non‑antibiotic options for digestive health.
Immune System Diseases
Studies explore immune‑related pathways and inflammatory processes, aiming to identify interventions that modulate the immune response and alleviate disease‑related symptoms.
- Inflammatory response modulation
- Evaluation of agents affecting immune signaling
- Assessment of safety in immune‑targeted therapies
- Biomarker analysis for immune activity
- Potential applications across autoimmune conditions
By probing immune mechanisms, the site helps lay groundwork for future treatments.
Nutritional and Metabolic Diseases
Research addresses metabolic risk factors, especially elevated lipoprotein(a) and cholesterol, to develop strategies that lower cardiovascular burden through nutritional and pharmacologic means.
- Elevated Lp(a) reduction studies
- Metabolic risk profiling
- Lipid metabolism intervention trials
- Impact on cardiovascular outcomes
- Safety evaluation of metabolic agents
These efforts aim to integrate metabolic health into broader cardiovascular prevention.
Otorhinolaryngologic Diseases
Clinical work includes evaluation of symptomatic treatments for acute pharyngitis, comparing new lozenge formulations with existing therapies to relieve throat discomfort.
- Acute pharyngitis symptom relief
- Efficacy of benzydamine hydrochloride lozenges
- Comparison with active comparators
- Patient comfort and recovery speed
- Safety profile of topical agents
The site’s trials support evidence‑based options for common ENT infections.
Pathological Conditions, Signs and Symptoms
The centre investigates chronic pain syndromes, focusing on chronic back pain to assess novel analgesic compounds and improve functional outcomes.
- Chronic back pain management
- Evaluation of add‑on pain therapies
- Impact on daily activity and quality of life
- Safety and tolerability in long‑term use
- Patient‑reported pain score improvements
These studies aim to expand therapeutic choices for individuals living with persistent pain.
Metabolism
Research delves into fundamental metabolic processes, particularly lipid and protein biomarkers, to understand how therapeutic interventions alter disease trajectories.
- Biomarker changes in LDL‑cholesterol
- Nt‑proBNP dynamics in heart failure
- Lp(a) level modulation over time
- Metabolic response to novel agents
- Correlation of metabolic shifts with clinical outcomes
Insights from these studies may inform personalized metabolic management strategies.
Mental Disorders
Clinical trials focus on mild to moderate major depressive disorder, testing oral agents that aim to improve mood scores and achieve remission without relying on traditional antidepressants.
- Major depressive disorder treatment efficacy
- MADRS score improvement
- Responder and remission rate analysis
- Safety and tolerability of novel anxiolytic compounds
- Impact on daily functioning and wellbeing
Hausarztzentrum Butendorf’s work contributes to expanding therapeutic options for mental health.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 6 therapeutic areas and 15 of 62 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 59 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 7 by active trials.
- 1AstraZeneca AB4active
lock +6 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB4trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hausarztzentrum Butendorf
lock Showing 1 of 18 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A multi- center, randomized, double-blind, placebo-controlled parallel–group, dose-finding study to evaluate efficacy, safety, and tolerability of DII235 in adults with elevated Lipoprotein(a) | Novartis Pharma AG | Phase II | Not Recruiting | Jan 2026 | — |
IMP list
lock Showing 1 of 62 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Adezunap | 4 | Unknown | 2023-11-02 | 2023-11-02 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.